En développement
Santé·04/06/2026Résumé IA
Trop-2 ADC offers new hope for aggressive metastatic triple-negative breast cancer
Metastatic triple-negative breast cancer (mTNBC) is aggressive and hard to treat. A new Trop-2 ADC drug, now covered by Taiwan's National Health Insurance, precisely targets cancer cells, improving outcomes and reducing side effects for patients like Ms. Chen, offering a new lease on life.
自
自由时报4 min de lecture